Carvedilol: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy

Drugs

Volumn 45, Issue 2, 1993, Pages 232-258

  McTavish, Donna ^a   Campoli Richards, Deborah ^a   Sorkin, Eugene M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA;

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; HYDROCHLOROTHIAZIDE; LABETALOL; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; PINDOLOL; PROPRANOLOL;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANGINA PECTORIS; BRONCHOSPASM; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG POTENTIATION; DRUG TOLERANCE; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; VASODILATATION; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; ANGINA PECTORIS; ANIMAL; CARBAZOLES; HEART FAILURE, CONGESTIVE; HEMODYNAMICS; HUMAN; HYPERTENSION; PROPANOLAMINES; VASODILATOR AGENTS;

EID: 0027506396     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199345020-00006     Document Type: Article

References (130)

1. A new molecule with vasodilating and β-adreno ceptor blocking properties
2. Phase I study of carvedilol (DQ-2466), a new β-blocker (The first report)
3. Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus
4. Pharmacological characteristics of the stereoisomers of carvedilol
5. 2α- and noradrenaline-induced contraction of human hand veins in vivo
6. Influence of carvedilol on the responsiveness of human hand veins to noradrenaline and dinoprost
7. Cardioprotective effects of carvedilol, a novel eta-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol
8. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes
9. β-Blockade with carvedilol selectively lowers cardiac adrenergic drive in the failing human heart
10. A prospective postmarketing surveillance study of carvedilol in the management of hypertension in general practice. Abstract
11. Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects
12. Clinical pharmacology of carvedilol in normal volunteers
13. Value of carvedilol in congestive heart failure secondary to coronary artery disease
14. Long term efficacy and safety of carvedilol, a new β-blocking agent with vasodilating properties, in patients with chronic ischaemic heart disease
15. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy
16. Effects of carvedilol on renal function
17. The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics
18. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension
19. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and pre-capillary vasodilating agent, in hypertensive patients
20. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension
21. Acute and long-term hemodynamic effects of carvedilol, a combined β-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients
22. 1 in non-insulin-dependent diabetics
23. 1 in non-insulin-dependent diabetes
24. Regression of left ventricular hypertrophy
25. Improvements in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial
26. Myocardial protection with carvedilol
27. Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure
28. Comparison of carvedilol and atenolol for angina pectoris
29. Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism
30. Long term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo
31. Effects of carvedilol on serum lipids in patients with essential hypertension
32. Pharmacokinetics of carvedilol in hypertensive patients with renal failure
33. A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension
34. 1 reduces infarct size in a canine model of acute myocardial infarction
35. Vascular effects of carvedilol, a new β-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery
36. Carvedilol for systemic hypertension
37. Vasodilating β-receptor antagonists: comparison of labetalol, carvedilol, dilevalol and brefanolol
38. Blood pressure lowering and cerebral blood flow: a comparison of the effects of carvedilol and propranolol on the cerebral circulation in hypertensive patients
39. Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension
40. Efficacy of carvedilol (BM14, 190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia
41. Adrenoceptor-blocking and cardiohemodynamic effects of carvedilol in animals
42. Multiple action compounds in angina pectoris
43. Evaluation of a new vasodilating β-blocking agent, carvedilol, in exertional angina using Holter monitoring
44. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension: An open, short term study
45. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure
46. Blood-pressure-lowering effect of carvedilol vs nitrendipine in geriatric hypertensives
47. Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension
48. Stereoselective antagonism by carvedilol against isoproterenol-induced facilitation of norepinephrine release in guinea-pig pulmonary arteries
49. Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease
50. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris
51. Comparison of effectiveness and safety of carvedilol (25mg; once daily) versus labetalol (200mg twice daily) in patients with mild to moderate hypertension using an ambulatory 24 hours Holter monitoring
52. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension
53. Resting and postexercise hemodynamic effects of carvedilol, a β-adrenergic blocker and precapillary vasodilator in hypertensive patients
54. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report
55. Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise
56. Carvedilol in hypertension: Effects on hemodynamics and 24 hours blood pressure
57. Neuro-protective effects of carvedilol, a new antihypertensive, in cultured rat cerebellar neurons and in gerbil global brain ischemia
58. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A Dose Response study
59. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension
60. Circadian antihypertensive profile of carvedilol (BM 14190)
61. Two-year follow-up of 24-hour indirect blood pressure monitoring: and open study
62. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension
63. Interaction of selected vasodilating β-Blockers with adrenergic receptors in human cardiovascular tissues
64. Effect of carvedilol and metoprolol on blood pressure, blood flow and vascular resistance
65. The use of carvedilol in elderly hypertensive patients
66. Pharmacokinetics of carvedilol in older and younger patients
67. Clinical experience with carvedilol
68. Effects of carvedilol on human isolated blood vessels
69. A comparison of carvedilol with a combination of propranolol and isosorbide dinitrate in the chronic treatment of stable angina
70. Stereoselective disposition of carvedilol on man after intravenous and oral administration of the racemic compound
71. Pharmacokinetics and disposition of carvedilol in humans
72. Pharmacokinetics and bio-availability of carvedilol in patient with liver cirrhosis
73. Metabolism of carvedilol in man
74. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol
75. 1-adrenoceptors
76. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol
77. Dose-effect relationship of carvedilol in essential hypertension: an open study
78. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension
79. Clinical efficacy of carvedilol in severe hypertension
80. Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension
81. Carvedilol improves left ventricular function in idiopathic dilated cardiomyopathy. Abstract
82. β-Blocker related improved in submaximal exercise tolerance in heart failure from idiopathic dilated cardiomyopathy (IDC). Abstract
83. Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise
84. Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise
85. High-performance liquid Chromatographic method for the determination of carvedilol and its desmethyl metabolite in body fluids
86. Response rate with respect to the blood pressure-lowering effect of the vasodilating and β-blocking agent carvedilol
87. Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon
88. Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity
89. Pharmacokinetic and pharmacodynamic interactions of combined acute administration of carvedilol and hydrochlorothiazide in hypertensive volunteers
90. The pharmacology of carvedilol
91. Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation
92. Carvedilol: a novel cardiovascular drug with multiple actions
93. Efficacy and safety of carvedilol in the treatment of hypertension
94. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects
95. Alpha and beta adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein
96. Effects of carvedilol on ventricular arrhythmias
97. Influence of carvedilol and propranolol on coronary blood flow
98. Cardioprotective effects of the vasodilator/beta-adrenoceptor blocker, carvedilol, in two models of myocardial infarction in the rat
99. Cardioprotective effects of carvedilol, a new beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs
100. Controlled trial of nifedipine in the treatment of Raynaud’s phenomenon
101. Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties
102. Studies on the mode of casodilating action of carvedilol
103. Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach
104. Vasodilatory effects of carvedilol and pindolol
105. Combination therapy with carvedilol and nicardipine in essential hypertension. An open study
106. Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial
107. Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydrazine
108. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol
109. Carvedilol reduces myocardial damage caused by coronary occlusion in dogs (abstract A3926)
110. Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r
111. Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide
112. Liquid Chromatographic assay and disposition of carvedilol in healthy volunteers
113. Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity
114. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker
115. Acute hemodynamic effects of the vasodilating and β-blocking agent carvedilol in comparison to propranolol
116. Effect of carvedilol on left ventricular function and mass in hypertension
117. Safety and antihypertensive efficacy of carvedilol and atenolol alone and n combination with hydrochlorothiazide
118. A comparison of the effect of carvedilol and nifedipine on the exercise capacity of patients with ischaemic heart disease. Abstract
119. Efficacy and tolerance of carvedilol in combination with a thiazide diuretic in the treatment of essential hypertension
120. A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension
121. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger
122. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper